Search the Newsreel

argenx SE: Objectif de Cours et Consensus des Analystes | ARGX | NL0010832176

Argenx stock steadies after Forte Biosciences deal and post-earnings pullback

Argenx stock is consolidating after a strong Q2 2026 earnings beat and a significant $2.2 billion acquisition of Forte Biosciences. Despite a recent pullback, the stock remains in positive territory year-to-date, with analysts maintaining a constructive outlook and an implied upside of roughly 23% …

Hedge Funds Favor argenx (ARGX) Over Forte Biosciences, Inc. (FBRX): Argenx Agrees to Buy Forte Biosciences

argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, …

argenx (ENXTBR:ARGX) Draws Fresh Valuation Debate, Is The Stock Overvalued Or Undervalued?

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, …

argenx (ENXTBR:ARGX) Stock Looks Fully Valued Despite Strong Returns And Deal Hopes

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how …

argenx (ENXTBR:ARGX) Is Considering A Forte Biosciences Acquisition

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. argenx (ENXTBR:ARGX) is set to consider and discuss the acquisition of Forte Biosciences, Inc. The potential deal would expand argenx's reach in biopharmaceutical …

argenx SE (ARGX) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on argenx SE (ARGX), a commercial-stage biopharmaceutical company focused on autoimmune diseases. It details the company's stock performance, key financial metrics, product pipeline, strategic partnerships, and analyst ratings. The article highlights argenx's main product, VYVGART, and several …

argenx SE (ARGX) Aktuelle Aktien-News

Halozyme's Q2 Earnings Beat Estimates, 2026 Outlook Raised, Stock Up

Halozyme Therapeutics HALO reported second-quarter 2026 adjusted earnings of $2.28 per share, which comprehensively beat the Zacks Consensus Estimate of $1.82. Earnings rose 48.1% year over year. Total revenues in the second quarter increased 48% year over year to $481 million. Revenues also surpassed …

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a tender offer to …

argenx SE: argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

argenx SE announced the commencement of a tender offer to acquire all outstanding shares of Forte Biosciences, Inc. for $77.00 per share in cash. This acquisition will make Forte Biosciences a wholly-owned subsidiary of argenx. Forte's Board of Directors has recommended that shareholders accept …

argenx (ENXTBR:ARGX) After Its Zacks Upgrade What Does The Valuation Narrative Say

argenx SE (ARGX) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

What Makes Argenx (ARGX) a New Buy Stock

Investors might want to bet on argenex SE (ARGX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. …

Argenx SE (ARGX) Prepares to Demonstrate Vyvgart’s Efficacy in Broader Autoimmune Diseases

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

argenx (ARGX) calls September 17 EGM to add two non-executive directors

argenx SE has announced an Extraordinary General Meeting of Shareholders (EGM) for September 17, 2026, in Amsterdam. The primary purpose of the EGM is to vote on the proposed appointments of Mr. Thomas M. Brakel and Mr. Khurem Farooq as non-executive directors to the …

argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026

argenx SE August 3, 2026 – 22:01 PM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Extraordinary General Meeting of …

argenx SE Revenue Breakdown – EURONEXT:ARGX

The article details argenx SE's revenue breakdown, highlighting that the company generated EUR 3.60 billion last year. The Antibody-based Medicines segment was the top performer, contributing EUR 3.68 billion, and the United States was the largest regional contributor with EUR 3.13 billion in revenue.

FTRE vs. ARGX: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. The best …

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited …

ARGX|argenx SE|Price:861.810|Chg%:-20.750

This article provides a comprehensive stock analysis of argenx SE (ARGX), highlighting its relatively stable fundamentals, good growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a "Buy" rating from multiple analysts, with an expected …

Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the …

argenx Bets $2.2 Billion on a Vitiligo Breakthrough: What the Forte Biosciences Deal Means for Both Stocks

The biopharma sector is in the middle of a transformation in which macroeconomic pressures and policy developments actively dictate corporate dealmaking. As leading pharmaceutical companies prepare for a $300 billion patent cliff in the second half of the decade, capital allocation has switched sharply …

Forte Biosciences (FBRX) Agrees To argenx Takeover As Tender Offer Nears

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which …

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Omeros (OMER)

Healthcare analysts have provided insights on Argenx Se (ARGX) and Omeros (OMER). Evercore ISI maintained a Buy rating on Argenx Se with a $1059.00 price target, while Needham maintained a Hold rating on Omeros. Both companies have analyst consensus ratings, with Argenx Se rated …

argenx (ENXTBR:ARGX) Could Be 15% Above Fair Value On The Forte Deal

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte's …

argenx signs agreement to buy Forte Biosciences for $2.2bn

argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset …

argenx (ENXTBR:ARGX) Stock Looks Fairly Valued With Modest Upside On Earnings

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx stock has delivered a very strong 202.6% return over the past five years, yet its current valuation checks point to a more mixed …

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debut; and Forte Biosciences, following …

Argenx enters biotech buyer class with $2.2B Forte takeout

Argenx has acquired Forte Biosciences for $2.2 billion, marking its entry into the large-cap biotech buyer class. This acquisition is funded entirely from Argenx's cash reserves, leveraging the financial success of its drug Vyvgart. The deal adds FB102, an anti-CD122 mAb, to Argenx's pipeline, …

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

Beauty pharmaceutical research by Chokniti-Studio via Shutterstock Forte Biosciences (FBRX) ripped higher on Monday after the Dutch immunology giant, Argenx (ARGX), announced a definitive agreement to acquire it for $2.2 billion. The all-cash transaction is expected to close in the third quarter of 2026 …

argenx (Nasdaq: ARGX) to acquire Forte Biosciences in $2.2B cash tender offer

argenx SE has agreed to acquire Forte Biosciences, Inc. for approximately $2.2 billion through a cash tender offer of $77 per share. This acquisition, expected to close in Q3 2026, will add Forte's lead anti-CD122 antibody FB102, which has shown positive Phase 1b data …

Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Argenx will acquire Forte Biosciences, the developer of an autoimmune disease drug that's shown early promise, in a deal worth up to …